Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: The randomized DIATOR trial

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Martin, Stephan ^a,e   Herder, Christian ^a   Schloot, Nanette C ^a,b   Koenig, Wolfgang ^c   Heise, Tim ^d   Heinemann, Lutz ^d   Kolb, Hubert ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Profil Institute for Metabolic Research   (Germany)

^e West German Centre of Diabetes and Health   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AUTOANTIBODY; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; PLACEBO; GLYCOSYLATED HEMOGLOBIN; HEPTANOIC ACID DERIVATIVE; LIPID; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; BILIARY COLIC; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GERMANY; HEADACHE; HELICOBACTER INFECTION; HUMAN; HYPERTRANSAMINASEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC REGULATION; MULTICENTER STUDY; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION;

ADULT; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; INSULIN-SECRETING CELLS; LIPIDS; MALE; PYRROLES; TREATMENT OUTCOME;

EID: 79952581919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017554     Document Type: Article

References (36)

1. The Canandian/European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 37: 1574-1582.
2. Waldron-Lynch F, Herold KC, (2009) Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinol Metab Clin North Am 38: 303-17, viii.
3. Blank N, Schiller M, Krienke S, Busse F, Schatz B, et al. (2007) Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol 179: 3613-3621.
4. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, et al. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 30: 2298-2313.
5. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Karnata T, Kallen J, et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692.
6. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, et al. (1992) Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 41: 1668-1671.
7. Roep BO, Heidenthal E, de Vries RR, Kolb H, Martin S, (1994) Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet 343: 1590-1593.
8. Martin S, Heidenthal E, Schulte B, Rothe H, Kolb H, (1998) Soluble forms of intercellular adhesion molecule-1 inhibit insulitis and onset of autoimmune diabetes. Diabetologia 41: 1298-1303.
9. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, et al. (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363: 2015-2021.
10. Paul F, Waiczies S, Wuerfel J, Bellman-Strobl J, Dorr J, et al. (2008) Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3: e1928.
11. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT, (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390-1395.
12. Rudick RA, Pace A, Rani MR, Hyde R, Paanzara M, et al. (2009) Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72: 1989-1993.
13. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, et al. (2010) Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 16: 450-454.
14. Rydgren T, Vaarala O, Sandler S, (2007) Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther 323: 180-185.
15. Palomer X, Calpe-Berdiel L, Verdaguer J, Carillo J, Pastor X, et al. (2005) Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes. Diabetologia 48: 1671-1673.
16. Lozanoska-Ochser B, Barone F, Pitzalis C, Peakman M, (2006) Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells. Diabetes 55: 1004-1010.
17. Zhang S, Yan X, Zhou PC, et al. (2008) [Effects of pravastatin in prevention of diabetes and mechanism thereof: experiment with non-obese diabetic mice]. Zhonghua Yi Xue Za Zhi 88: 568-572.
18. Contreras JL, Smyth CA, Bilbao G, Young CJ, Thompson JA, Eckhoff DE, (2002) Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation 74: 1063-1069.
19. Baker WL, Talati R, White CM, Coleman CI, (2010) Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 87: 98-107.
20. Kolb H, Gale EA, (2001) Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes? Diabetologia 44: 1349-1353.
21. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, et al. (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53: 250-264.
22. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Batllino T, Haastert B, et al. (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31: 1966-1971.
23. Kwak B, Mulhaupt F, Myit S, Mach F, (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
24. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, et al. (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25: 1231-1236.
25. Blum A, Shamburek R, (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203: 325-330.
26. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, et al. (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 48: 233-242.
27. Kim YC, Kim KK, Shevach EM, (2010) Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology 130: 484-493.
28. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
29. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, et al. (2003) Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 93: 948-956.
30. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 203: 401-412.
31. Bu DX, Tarrio M, Grabie N, Zhang Y, Yamazaki H, et al. (2010) Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses. J Clin Invest 120: 1961-1970.
32. Marchand KC, Arany EJ, Hill DJ, (2010) Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent. Am J Physiol Endocrinol Metabol 299: E92-E100.
33. The Diabetes Control and Complications Trial Research Group (1998) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128: 517-523.
34. Herder C, Peltonen M, Koenig W, Sutfels K, Lindstrom J, et al. (2009) Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia 52: 433-442.
35. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, et al. (2006) Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 49: 921-929.
36. Hanifi-Moghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H, (2003) An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52: 1137-1142.